Results 171 to 180 of about 284,051 (203)

Heterozygous familial hypercholesterolemia case study

Journal of the American Academy of Nurse Practitioners, 2010
Abstract  Purpose: To examine a case of heterozygous familial hypercholesterolemia (HeFH) in a primary care setting and to review the epidemiology, pathophysiology, etiology, and treatment guidelines to reduce the mortality related to this disease process. Data Sources: Findings from the history, physical exam, and laboratory results of a young French
openaire   +2 more sources

Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

Atherosclerosis, 2004
Familial hypercholesterolemia (FH) is a genetic disorder of lipoprotein metabolism characterized by very high plasma concentrations of low density lipoprotein cholesterol (LDLc), tendon xanthomas and increased risk of premature coronary heart disease (CHD). FH is a public health problem throughout the world.
openaire   +2 more sources

Increased Prevalence of Coronary Ectasia in Heterozygous Familial Hypercholesterolemia

Circulation, 1995
Background Although coronary atherosclerosis most commonly produces clinical effects as a result of stenosis, aneurysmal disease also occurs. We have found an increased prevalence of ectasia and aneurysmal disease in familial hypercholesterolemia (FH) suggesting a link between plasma lipoproteins and coronary aneurysms.
K, Sudhir, T A, Ports, T M, Amidon, J J, Goldberger, V, Bhushan, J P, Kane, P, Yock, M J, Malloy   +7 more
openaire   +2 more sources

Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia

Atherosclerosis, 2019
Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and increased cardiovascular disease risk. Despite multiple LDL-C-lowering therapies, many HeFH patients do not reach LDL-C targets. Mipomersen, an antisense oligonucleotide against apolipoprotein B (apoB),
Nandhini Sehar, Christie Ballantyne, Alberico Luigi Catapano   +2 more
exaly   +3 more sources

Treatment of heterozygous familial hypercholesterolemia: atorvastatin versus simvastatin

Atherosclerosis Supplements, 2001
This study compares the cholesterol-lowering efficacy of atorvastatin and simvastatin in attainment of the National Cholesterol Education Program (NCEP) guidelines LDL-cholesterol (LDL-C) goal in patients with heterozygous familial hypercholesterolemia (HFH).
BO, Mario, M. T. NICOLELLO, U. FIANDRA, G. MERCADANTE, T. PILIEGO, F. FABRIS   +5 more
openaire   +3 more sources

Novel treatment options for the management of heterozygous familial hypercholesterolemia

Expert Review of Clinical Pharmacology, 2017
Even though statins represent the mainstay of treatment of heterozygous familial hypercholesterolemia (FH), their low-density lipoprotein cholesterol (LDL-C) lowering efficacy is finite and most patients with FH will not achieve LDL-C targets with statin monotherapy.
Georgios, Polychronopoulos, Konstantinos, Tziomalos   +1 more
openaire   +2 more sources

Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia

Annals of Internal Medicine, 1987
To evaluate the efficacy and tolerability of lovastatin under controlled conditions in heterozygous familial hypercholesterolemia.Randomized, double-blind, placebo-controlled, multicenter trial.Five lipid clinics with a central laboratory and coordinating center.101 adult patients with heterozygous familial hypercholesterolemia.Patients were on a lipid-
RICHARD J. HAVEL, DONALD B. HUNNINGHAKE, D. ROGER ILLINGWORTH, ROBERT S. LEES, EVAN A. STEIN, JONATHAN A. TOBERT, SANDRA R. BACON, JAMES A. BOLOGNESE, PHILIP H. FROST, GLENN E. LAMKIN, ANN M. LEES, ARTHUR S. LEON, KAY GARDNER, G. JOHNSON, M. J. MELLIES, PATRICIA A. RHYMER, P. TUN   +16 more
openaire   +2 more sources

Treatment of children with heterozygous familial hypercholesterolemia

International Journal of Cardiology, 2020
Željko, Reiner, Amirhossein, Sahebkar
openaire   +2 more sources

Heterozygous familial hypercholesterolemia

Atherosclerosis, 1979
C. Gagné, S. Moorjani, D. Brun, M. Toussaint, P.-J. Lupien   +4 more
openaire   +1 more source

[Colestipol in the treatment of heterozygous familial hypercholesterolemia].

Casopis lekaru ceskych, 1992
In the specialized clinic for disorders of the lipid metabolism 27 patients, 8 men and 19 women, heterozygotes with familial hypercholesterolaemia were treated for 8 weeks with Colestid (colestipol bags a 5 g, Upjohn, Belgium). The administered dose was 15 g colestipol per day. After colestipol treatment the authors recorded a statistically significant
R, Ceska, J, Sobra, H, Toschnerová, J, Traurig   +3 more
openaire   +1 more source